CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Sep. 27, 2025	Sep. 28, 2024
Cash Flows from Operating Activities:
Net income	$ 72,715	$ 72,204
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	57,013	58,353
Amortization of fair value inventory step-up	4,491	8,978
Share-based compensation expense	16,901	14,485
Impairment of intangible assets	8,584	2,391
Gain on repurchase of convertible senior notes, net	0	(12,600)
Gains on sales of property, plant and equipment	(318)	(14,412)
Deferred income taxes	(3,956)	(6,176)
Other non-cash operating activities	2,679	4,523
Change in operating assets and liabilities:
Change in accounts receivable	(3,702)	(1,608)
Change in inventories	25,058	(47,008)
Change in prepaid income taxes	3,136	(3,713)
Change in other assets and other liabilities	(23,688)	(13,890)
Change in accounts payable and accrued expenses	(30,197)	(40,125)
Net cash provided by operating activities	128,716	21,402
Cash Flows from Investing Activities:
Capital expenditures	(8,770)	(15,089)
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment	(29,149)	(6,754)
Acquisitions	0	(150,906)
Proceeds from sale of property, plant and equipment	417	20,551
Other investments	(25,966)	(10,366)
Net cash used in investing activities	(63,468)	(162,564)
Cash Flows from Financing Activities:
Proceeds from issuance of convertible notes	0	700,000
Repurchase of convertible senior notes	0	(185,500)
Purchase of capped call related to convertible notes	0	(88,200)
Term loan borrowings	0	250,000
Term loan redemption	0	(262,500)
Payments on revolving facility	0	50,000
Repayment of term loan borrowings	(3,125)	(1,563)
Debt issuance costs	0	(23,135)
Share repurchases	(75,000)	(75,000)
Proceeds from employee stock purchase plan	3,476	3,441
Proceeds from exercise of stock options	525	1,212
Cash used to net share settle employee equity awards	(4,795)	(9,794)
Other financing activities	(75)	(73)
Net cash (used in) provided by financing activities	(78,994)	258,888
Effect of exchange rates on cash and cash equivalents	3,409	2,757
Net Change in Cash and Cash Equivalents	(10,337)	120,483
Cash and Cash Equivalents at Beginning of Period	306,763	178,800
Cash and Cash Equivalents at End of Period	$ 296,426	$ 299,283